Skip to main content

Drug Interactions between bexagliflozin and ginseng

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ginseng bexagliflozin

Applies to: ginseng and bexagliflozin

MONITOR: Coadministration of ginseng with antidiabetic drugs may potentiate the risk of hypoglycemia. Clinical data are conflicting. Some small studies have reported that ginseng reduced the blood levels of glucose and/or glycosylated hemoglobin (HbA1c) in diabetic patients, whereas others have not. Furthermore, the lack of standardized preparations of ginseng may limit the generalization of study results. In a double-blind, randomized cross-over trial, 24 diabetic patients received either 1 g/meal (3 g/day) of American ginseng (AG) extract or placebo for 8 weeks while maintaining their original antidiabetic treatments. Compared to placebo, AG significantly reduced HbA1c by 0.29% and fasting blood glucose by 0.71 mmol/L. In another study, 36 non-insulin dependent diabetic patients received 100 mg or 200 mg ginseng extract containing 4 mg or 8 mg of ginsenoside, respectively or placebo once daily for 8 weeks. Compared to placebo, HbA1c was reduced by 0.5% and fasting blood glucose by 0.9 mmol/L in the 200 mg ginseng extract group. However, in contrast, other randomized, double-blind, placebo controlled studies reported no effect of ginseng on HbA1c.

MANAGEMENT: Until more information is available, blood glucose should be monitored if antidiabetic agents are used concomitantly with ginseng. Patients should be advised on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia), how to treat it, and to contact their doctor if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.

References

  1. Vuksan V, Sievenpiper JL, Koo VY, et al. (2000) "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med, 160, p. 1009-13
  2. Carabin IG, Burdock GA, Chatzidakis C (2000) "Safety assessment of panax ginseng." Int J Toxicol, 19, p. 293-301
  3. Vuksan V, Sung MK, Sievenpiper JL, et al. (2008) "Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety." Nutr Metab Cardiovasc Dis, 18, p. 46-56
  4. Vuksan V, Sievenpiper JL, Koo VY, et al. (2000) "Efficacy and safety of Panax ginseng berry extract on glycemic control: A 12-wk randomized, double-blind, and placebo controlled trial." Arch Intern Med, 160, p. 1009-13
  5. Vuskan V, Xu ZZ, Jovanovski E, et al. (2019) "Efficacy and safety of American ginseng (Panax quinquefolius L) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial." Eur J Nutr, 58, p. 1237-45
  6. Sotaniemi EA, Haapakoski E, Rautio A (1995) "Ginseng therapy in non-insulin-dependent diabetic patients." Diabetes Care, 18, p. 1373-5
  7. Win HH, Anderson R (2019) "Hypoglycemia due to "conception-enhancing" oral supplement." Endocr Pract, 24, p. 88-9
View all 7 references

Switch to consumer interaction data

Drug and food interactions

Moderate

bexagliflozin food

Applies to: bexagliflozin

GENERALLY AVOID: Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes. Hypoglycemia most frequently occurs during acute consumption of alcohol. Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise. The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia. Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion. By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia. Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes. A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.

MANAGEMENT: Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis. Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan. Alcohol should not be consumed on an empty stomach or following exercise.

References

  1. Jerntorp P, Almer LO (1981) "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand, 656, p. 33-6
  2. Jerntorp P, Almer LO, Holin H, et al. (1983) "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol, 24, p. 237-42
  3. Barnett AH, Spiliopoulos AJ, Pyke DA, et al. (1983) "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia, 24, p. 213-5
  4. Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A (1987) "Interaction of ethanol and glipizide in humans." Diabetes Care, 10, p. 683-6
  5. (2002) "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals
  6. (2002) "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals
  7. "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  8. Skillman TG, Feldman JM (1981) "The pharmacology of sulfonylureas." Am J Med, 70, p. 361-72
  9. (2002) "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care, 25(Suppl 1), S50-S60
  10. Cerner Multum, Inc. "UK Summary of Product Characteristics."
View all 10 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.